An ethinyl estradiol-levonorgestrel containing oral contraceptive does not alter cytochrome p4502c9 in vivo activity

Ganesh Cherala, Jacob Pearson, Cheryl Maslen, Alison Edelman

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Oral contraceptives have been in wide use for more than 50 years. Levonorgestrel, a commonly employed progestin component of combined oral contraceptives, was implicated in drug-drug interactions mediated via CYP2C9. Although in vitro studies refuted this interaction, there are no confirmatory in vivo studies. In the current study, we examined the phenotypic status of CYP2C9 using low-dose (125 mg) tolbutamide before and after oral contraceptive use in reproductive age women. Blood was collected 24 hours after the tolbutamide oral dose was administered, plasma was isolated, and tolbutamide concentration (C24) was measured using liquid chromatography-mass spectrometry. The natural logarithm of tolbutamide C24, a metric for CYP2C9 phenotype, was found to be equivalent (within 80%-125% equivalency boundaries) before and after oral contraceptive use. In conclusion, levonorgestrel-containing oral contraceptives, the most commonly used form of oral contraception, do not affect the status of the CYP2C9 enzyme. This suggests that it is safe to coadminister levonorgestrel-containing oral contraceptives and CYP2C9 substrates, which include a wide array of drugs.

Original languageEnglish (US)
Pages (from-to)323-325
Number of pages3
JournalDrug Metabolism and Disposition
Volume42
Issue number3
DOIs
StatePublished - Mar 2014

Fingerprint

Cytochromes
Oral Contraceptives
Tolbutamide
Levonorgestrel
Contraceptives, Oral, Combined
Progestins
Contraception
Drug Interactions
Liquid Chromatography
Pharmaceutical Preparations
Mass Spectrometry
Cytochrome P-450 CYP2C9
levonorgestrel drug combination ethinyl estradiol
Phenotype
Enzymes

ASJC Scopus subject areas

  • Pharmacology
  • Pharmaceutical Science

Cite this

An ethinyl estradiol-levonorgestrel containing oral contraceptive does not alter cytochrome p4502c9 in vivo activity. / Cherala, Ganesh; Pearson, Jacob; Maslen, Cheryl; Edelman, Alison.

In: Drug Metabolism and Disposition, Vol. 42, No. 3, 03.2014, p. 323-325.

Research output: Contribution to journalArticle

@article{66457fe96c2a46ab9f2720df2856dd1c,
title = "An ethinyl estradiol-levonorgestrel containing oral contraceptive does not alter cytochrome p4502c9 in vivo activity",
abstract = "Oral contraceptives have been in wide use for more than 50 years. Levonorgestrel, a commonly employed progestin component of combined oral contraceptives, was implicated in drug-drug interactions mediated via CYP2C9. Although in vitro studies refuted this interaction, there are no confirmatory in vivo studies. In the current study, we examined the phenotypic status of CYP2C9 using low-dose (125 mg) tolbutamide before and after oral contraceptive use in reproductive age women. Blood was collected 24 hours after the tolbutamide oral dose was administered, plasma was isolated, and tolbutamide concentration (C24) was measured using liquid chromatography-mass spectrometry. The natural logarithm of tolbutamide C24, a metric for CYP2C9 phenotype, was found to be equivalent (within 80{\%}-125{\%} equivalency boundaries) before and after oral contraceptive use. In conclusion, levonorgestrel-containing oral contraceptives, the most commonly used form of oral contraception, do not affect the status of the CYP2C9 enzyme. This suggests that it is safe to coadminister levonorgestrel-containing oral contraceptives and CYP2C9 substrates, which include a wide array of drugs.",
author = "Ganesh Cherala and Jacob Pearson and Cheryl Maslen and Alison Edelman",
year = "2014",
month = "3",
doi = "10.1124/dmd.113.054346",
language = "English (US)",
volume = "42",
pages = "323--325",
journal = "Drug Metabolism and Disposition",
issn = "0090-9556",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "3",

}

TY - JOUR

T1 - An ethinyl estradiol-levonorgestrel containing oral contraceptive does not alter cytochrome p4502c9 in vivo activity

AU - Cherala, Ganesh

AU - Pearson, Jacob

AU - Maslen, Cheryl

AU - Edelman, Alison

PY - 2014/3

Y1 - 2014/3

N2 - Oral contraceptives have been in wide use for more than 50 years. Levonorgestrel, a commonly employed progestin component of combined oral contraceptives, was implicated in drug-drug interactions mediated via CYP2C9. Although in vitro studies refuted this interaction, there are no confirmatory in vivo studies. In the current study, we examined the phenotypic status of CYP2C9 using low-dose (125 mg) tolbutamide before and after oral contraceptive use in reproductive age women. Blood was collected 24 hours after the tolbutamide oral dose was administered, plasma was isolated, and tolbutamide concentration (C24) was measured using liquid chromatography-mass spectrometry. The natural logarithm of tolbutamide C24, a metric for CYP2C9 phenotype, was found to be equivalent (within 80%-125% equivalency boundaries) before and after oral contraceptive use. In conclusion, levonorgestrel-containing oral contraceptives, the most commonly used form of oral contraception, do not affect the status of the CYP2C9 enzyme. This suggests that it is safe to coadminister levonorgestrel-containing oral contraceptives and CYP2C9 substrates, which include a wide array of drugs.

AB - Oral contraceptives have been in wide use for more than 50 years. Levonorgestrel, a commonly employed progestin component of combined oral contraceptives, was implicated in drug-drug interactions mediated via CYP2C9. Although in vitro studies refuted this interaction, there are no confirmatory in vivo studies. In the current study, we examined the phenotypic status of CYP2C9 using low-dose (125 mg) tolbutamide before and after oral contraceptive use in reproductive age women. Blood was collected 24 hours after the tolbutamide oral dose was administered, plasma was isolated, and tolbutamide concentration (C24) was measured using liquid chromatography-mass spectrometry. The natural logarithm of tolbutamide C24, a metric for CYP2C9 phenotype, was found to be equivalent (within 80%-125% equivalency boundaries) before and after oral contraceptive use. In conclusion, levonorgestrel-containing oral contraceptives, the most commonly used form of oral contraception, do not affect the status of the CYP2C9 enzyme. This suggests that it is safe to coadminister levonorgestrel-containing oral contraceptives and CYP2C9 substrates, which include a wide array of drugs.

UR - http://www.scopus.com/inward/record.url?scp=84893856196&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84893856196&partnerID=8YFLogxK

U2 - 10.1124/dmd.113.054346

DO - 10.1124/dmd.113.054346

M3 - Article

VL - 42

SP - 323

EP - 325

JO - Drug Metabolism and Disposition

JF - Drug Metabolism and Disposition

SN - 0090-9556

IS - 3

ER -